Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Ephedrine supplements label warning against use for weight loss urged by pediatricians.

This article was originally published in The Tan Sheet

Executive Summary

EPHEDRINE LABEL WARNING AGAINST USE FOR WEIGHT LOSS SUGGESTED by the American Academy of Pediatrics in Aug. 15 comments to FDA. Noting the agency has proposed that ephedrine-containing dietary supplements should not be allowed to carry weight loss claims, AAP recommends additional "inclusion of statements advising that such products are not intended for use as an intervention for weight loss." The group supports "full disclosure labeling of such products and oppose[s] any suggestive claims designed to make these products more appealing to children, particularly adolescents."

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS087500

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel